SHERIDAN, WYOMING - March 31, 2026 - Medtech companies planning 2026 leadership recognition, industry positioning, and internal talent visibility now have a defined nomination window tied to one of the sector's highest-profile annual gatherings. AdvaMed has opened nominations through April 10 for three 2026 honors: the AdvaMed Lifetime Achievement Award, the AdvaMedDx Lifetime of Leadership & Service Award, and the AdvaMed Imaging Röntgen Award. All three awards are scheduled to be presented at The MedTech Conference, set for October 18-21, 2026, in Boston.
Awards scope and eligibility
The AdvaMed Lifetime Achievement Award is aimed at individuals with significant, prolonged contributions to the medtech industry. Eligibility rules in the source narrow the field to leaders who have retired from day-to-day medtech responsibilities for at least one full calendar year and who are no longer serving as board chair for their signature employer. That makes the award a recognition of long-horizon industry influence rather than current executive performance.
The diagnostics and imaging categories target different parts of the workforce. The AdvaMedDx Lifetime of Leadership & Service Award recognizes individuals with significant and sustained contributions to the in vitro diagnostics industry. The AdvaMed Imaging Röntgen Award, by contrast, is designed for a mid-level employee at an AdvaMed member company whose work has significantly served not only their employer but the broader medical imaging industry. The source notes that the diagnostics award was established in 2025 and that the Röntgen Award honors Wilhelm Conrad Röntgen, identified as the discoverer of X-rays and a Nobel laureate.
Why the nomination cycle matters
The awards are linked directly to The MedTech Conference, giving them visibility beyond a standalone recognition program. For companies, that connection matters because honorees are recognized during a major industry event attended by executives, policy stakeholders, and member organizations across medtech segments. With nominations open only through April 10, the timeline compresses the internal review period for trade associations, member companies, and peers deciding whom to put forward.
The source also adds context around continuity and precedent. AdvaMed points readers to criteria and past winners for the Lifetime Achievement Award, and it references Mike Mussallem as the 2025 Lifetime Achievement winner. For diagnostics, the source highlights Charles Fleischman as the inaugural winner of the AdvaMedDx Lifetime of Leadership & Service Award. Those details indicate that the 2026 cycle is building on an established flagship honor, a newer diagnostics-specific recognition track, and an imaging award that spotlights contributions below the top executive tier.
Business impact
HR leaders and corporate communications teams at medtech manufacturers now need to decide whether to allocate time before April 10 to assemble nomination packages, validate candidate eligibility, and align submissions with company reputation goals for 2026. In practice, that means identifying retired sector leaders for the Lifetime Achievement category, diagnostics veterans for the AdvaMedDx award, or mid-level imaging employees whose industry service extends beyond their own company. These choices can shape how firms present leadership depth, succession legacy, and functional expertise during the 2026 conference cycle.
Business unit heads in diagnostics and imaging, along with association affairs teams, also get a concrete signal about where AdvaMed is placing recognition emphasis in 2026: sustained leadership in in vitro diagnostics and broader industry contribution from imaging professionals. That can influence conference planning, stakeholder outreach, and recognition budgets tied to Boston in October. For member companies, the Röntgen Award is especially relevant because it creates a formal pathway to elevate mid-level talent, not just senior executives, which can affect retention, internal advancement narratives, and decisions on who represents the company in industry working groups and public-facing forums.